Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 3/2023

09-08-2022 | Insulins | Original Article

Current insulinization trends in India

Authors: Dhruvi Hasnani, Bharat Saboo, Ashutosh Chaturvedi, Mahuya Sikdar, Arun Shankar, Rupam Choudhury, Banshi Saboo, Nishtha Manish Singh, Santosh Jha, Vipul Chavda

Published in: International Journal of Diabetes in Developing Countries | Issue 3/2023

Login to get access

Abstract

Background

Hyperglycemia-associated micro- and macro-vascular complications remain the leading cause of premature morbidity and mortality among the diabetic population worldwide. Poor glycemic control due to clinical inertia towards insulin treatment is a major cause behind the development of diabetic complications. In this paper, we analyze different strategies of insulin treatment initialization and titration practiced in India.

Methods

The response of 367 healthcare professionals (HCPs) across the country was recorded based on a survey on demographics, treatment regimens, and patient behavior. For analysis, the responses from HCPs were segregated into six regions, north, south, east, west, and central, covering the entire country.

Results

The survey revealed that 59.1% HCPs preferred using three oral anti-diabetic drugs (OADs) before starting insulin therapy while 12.5% initiated insulin as the last option after trying all available OADs. Besides, 61% HCPs across India considered initiating insulin in type 2 diabetes mellitus (T2DM) patients when the patients (i) failed to achieve glycemic targets with current OADs, or (ii) could not tolerate OADs, or (iii) required a more flexible therapy. In T2DM patients, 52.9% HCPs chose basal only insulin during initiation. In comparison, 63.8% HCPs used basal bolus while initiating insulin in type 1 DM (T1DM) patients. Pan-India, 53.4% HCPs preferred analogue premix while 46.6% HCPs opted for human premix. Next, 98.9% HCPs counselled patients about the risk of hypoglycemia upon initiation of insulin.

Conclusion

This survey outlines an urgent need of reducing the clinical inertia against insulin initialization in Indian settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mohan V, Shah SN, Joshi SR, Seshiah V, Sahay BK, Banerjee S, Wangnoo SK, Kumar A, Kalra S, Unnikrishnan AG, Sharma SK, Rao PV, Akhtar S, Shetty RV, das A, DiabCare India 2011 Study Group. Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study. Indian J Endocrinol Metab. 2014;18:370–8.CrossRefPubMedPubMedCentral Mohan V, Shah SN, Joshi SR, Seshiah V, Sahay BK, Banerjee S, Wangnoo SK, Kumar A, Kalra S, Unnikrishnan AG, Sharma SK, Rao PV, Akhtar S, Shetty RV, das A, DiabCare India 2011 Study Group. Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study. Indian J Endocrinol Metab. 2014;18:370–8.CrossRefPubMedPubMedCentral
2.
go back to reference Omar MS, Khudada K, Safarini S, Mehanna S, Nafach J. DiabCare survey of diabetes management and complications in the Gulf countries. Indian J Endocrinol Metab. 2016;20:219–27.CrossRefPubMedPubMedCentral Omar MS, Khudada K, Safarini S, Mehanna S, Nafach J. DiabCare survey of diabetes management and complications in the Gulf countries. Indian J Endocrinol Metab. 2016;20:219–27.CrossRefPubMedPubMedCentral
3.
go back to reference Tandon N, Kalra S, Balhara YP, Baruah MP, Chadha M, Chandalia HB, et al. Forum for injection technique (FIT), India: The Indian recommendations 2.0, for best practice in insulin injection technique, 2015. Indian J Endocrinol Metab. 2015;19:317–31.CrossRefPubMedPubMedCentral Tandon N, Kalra S, Balhara YP, Baruah MP, Chadha M, Chandalia HB, et al. Forum for injection technique (FIT), India: The Indian recommendations 2.0, for best practice in insulin injection technique, 2015. Indian J Endocrinol Metab. 2015;19:317–31.CrossRefPubMedPubMedCentral
4.
go back to reference Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications. 2015;29:295–301.CrossRefPubMed Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications. 2015;29:295–301.CrossRefPubMed
5.
go back to reference Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R̈, Kleinebreil L, on behalf of the International DAWN Advisory Panel. on behalf of the International DAWN Advisory Board. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study (DAWN). Diabetes Care. 2005;28:2673–9.CrossRefPubMed Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R̈, Kleinebreil L, on behalf of the International DAWN Advisory Panel. on behalf of the International DAWN Advisory Board. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study (DAWN). Diabetes Care. 2005;28:2673–9.CrossRefPubMed
6.
go back to reference Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35:1014–22.CrossRefPubMed Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35:1014–22.CrossRefPubMed
7.
go back to reference Dailey G, Aurand L, Stewart J, Ameer B, Zhou R. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus. J Diabetes. 2014;6:176–83.CrossRefPubMed Dailey G, Aurand L, Stewart J, Ameer B, Zhou R. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus. J Diabetes. 2014;6:176–83.CrossRefPubMed
8.
9.
go back to reference Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55:636–43.CrossRefPubMed Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55:636–43.CrossRefPubMed
10.
go back to reference The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 1993;329:977-986. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 1993;329:977-986.
11.
12.
go back to reference Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R̈, Kleinebreil L, on behalf of the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28:2673–9.CrossRefPubMed Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R̈, Kleinebreil L, on behalf of the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28:2673–9.CrossRefPubMed
13.
go back to reference Data on file. Action Asia: Indian country session summary, 29th Oct 2011. Data on file. Action Asia: Indian country session summary, 29th Oct 2011.
14.
go back to reference Joshi SR, Das AK, Vijay VJ, Mohan V. Challenges in diabetes care in India: Sheer numbers, lack of awareness and inadequate control. J Assoc Physicians India. 2008;56:443–50.PubMed Joshi SR, Das AK, Vijay VJ, Mohan V. Challenges in diabetes care in India: Sheer numbers, lack of awareness and inadequate control. J Assoc Physicians India. 2008;56:443–50.PubMed
15.
go back to reference Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–46.CrossRefPubMed Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–46.CrossRefPubMed
16.
go back to reference American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S98–110.CrossRef American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S98–110.CrossRef
17.
go back to reference International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1–52.CrossRef International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1–52.CrossRef
18.
go back to reference Chawla R, Makkar BM, Aggarwal S, Bajaj S, Das AK, Ghosh S, et al. RSSDI consensus recommendations on insulin therapy in the management of diabetes. Int J Diabetes Dev Ctries. 2019;39:43–92.CrossRef Chawla R, Makkar BM, Aggarwal S, Bajaj S, Das AK, Ghosh S, et al. RSSDI consensus recommendations on insulin therapy in the management of diabetes. Int J Diabetes Dev Ctries. 2019;39:43–92.CrossRef
19.
go back to reference Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: Analogue or human? Diabetes Obes Metab. 2007;9:630–9.CrossRefPubMed Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: Analogue or human? Diabetes Obes Metab. 2007;9:630–9.CrossRefPubMed
20.
go back to reference Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1:28–34.CrossRefPubMed Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1:28–34.CrossRefPubMed
21.
go back to reference Seshiah V, Das AK, Balaji V, Joshi SR, Parikh MN. Gupta S;et al. Gestational Diabetes Mellitus Guidelines. JAPI. 2006;54:622–8.PubMed Seshiah V, Das AK, Balaji V, Joshi SR, Parikh MN. Gupta S;et al. Gestational Diabetes Mellitus Guidelines. JAPI. 2006;54:622–8.PubMed
Metadata
Title
Current insulinization trends in India
Authors
Dhruvi Hasnani
Bharat Saboo
Ashutosh Chaturvedi
Mahuya Sikdar
Arun Shankar
Rupam Choudhury
Banshi Saboo
Nishtha Manish Singh
Santosh Jha
Vipul Chavda
Publication date
09-08-2022
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2023
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-022-01123-x

Other articles of this Issue 3/2023

International Journal of Diabetes in Developing Countries 3/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine